Asia Fighting Malaria
Saturday, March 25, 2017
  Search 
Home
Opportunities
Supports Us
About Us
 
 
Please enter your email here, we would like to keep you informed.
 
 
Connect With Us - Facebook RSS
<March 2017>
SuMoTuWeThFrSa
1234
567891011
12131415161718
19202122232425
262728293031
Sections
Malaria Medicines
Malaria Burden
Malaria Prevention
Malaria Control
Malaria Research
Malaria Economics
Malaria Policy
Malaria Diagnosis
 Malaria Medicines
 
One in three malaria drugs in Africa ineffective
Campaign for Fighting Diseases, United Kingdom Tuesday, May 06, 2008

Press Release
35% of antimalarial drugs sold in six major African cities failed basic quality tests according to a study published last week in PLoS ONE , a peer-reviewed open-access journal. The study further found that artemisinin monotherapies, which the World Health Organisation explicitly rejects as substandard, remain common in Africa. Substandard antimalarial drugs cause an estimated 200,000 avoidable deaths each year. “Our study shows that efforts to increase access to quality antimalarial drugs in Africa are increasingly important,” said Dr. Roger Bate, lead author on the study.

35% of antimalarial drugs sold in six major African cities failed basic quality tests according to a study published last week in PLoS ONE , a peer-reviewed open-access journal. The study further found that artemisinin monotherapies, which the World Health Organisation explicitly rejects as substandard, remain common in Africa. Substandard antimalarial drugs cause an estimated 200,000 avoidable deaths each year.

 

“Our study shows that efforts to increase access to quality antimalarial drugs in Africa are increasingly important,” said Dr. Roger Bate, Resident Fellow at the American Enterprise Institute and lead author on the study. “Substandard drugs not only endanger lives today, but also jeopardize future malaria treatment strategies by accelerating parasite resistance.”

Artemisinin combination therapies, or ACTs, lower the chances of developing parasite resistance and reducing treatment efficacy. Yet a third of the drugs collected in the study were artemisinin monotherapies. 42% of them failed and 78% were manufactured after the World Health Organisation proscribed them in January 2006.

 

“Malaria surged through Africa in the 1990s, fueled by resistance to chloroquine and other historically effective drugs,” said Richard Tren, Director of Africa Fighting Malaria , (www.fightingmalaria.org) a non-profit advocacy group. “Because regulation and post-market surveillance of drugs is so poor in most malarial countries, ACTs now risk the same fate.”

The World Health Assembly resolved in May 2007 to stop the production and marketing of artemisinin monotherapies. But according to the World Health Organisation, only 40 of 74 global manufacturers have agreed in principle to stop production, and 42 countries – 18 of them in sub-Saharan Africa – still allow companies to market these drugs.

Africa Fighting Malaria also released a report on malaria treatment policy in Africa, examining the challenges of pharmaceutical regulation and production in Africa, and calling for stronger global leadership from donors on drug procurement standards.

 

“Under the Global Fund’s ‘Option C’, (see CFD bulletin March 10th for more information) poor countries can use taxpayer funds to buy untested drugs of uncertain quality,” said Richard Tren. “Option C was intended to increase incentives for nascent ACT producers to enter the market and foster competition. It has accomplished this, but it has not provided any incentives for these companies to go the extra step and submit to bioequivalence testing by a stringent regulatory authority.”

 

Post-market surveillance and pharmacovigilance are severely limited in Africa, yet crucial to detecting bad drugs and the inevitable development of parasite resistance for an at-risk population of 700 million. As the PLoS ONE study argues, a fraction of the current global budget for malaria control could support a decentralized network for basic drug quality testing in Africa using Minilabs, portable chemistry sets, or equivalent technologies.

 

Download the study here.

This article was published in the Campaign for Fighting Diseases on Tuesday, May 06, 2008.
Author :
Tags- Find more articles on - ineffective drugs | malaria artemisinin | malaria medicine | spurious medicine

Post your Comments on this Article

Name  
Email    
Comment  
Comments will be moderated

More Related Articles
Malaria Medicines
More Articles


 
An Initiative of
LIBERTY INSTITUTE, INDIA
All rights reserved.